Cure Duchenne

Search Intent Cockpit

Cure Duchenne Form 990, Revenue, CEO Pay, and IRS Filing Signals

Cure Duchenne is surfaced here as a decision-ready nonprofit financial profile, not just a charity listing. The page consolidates IRS Form 990 revenue, expenses, assets, tax-exempt classification, executive compensation, mission score, red flags, and year-by-year filing history so donors, researchers, journalists, and grant teams can answer the common search questions around Cure Duchenne in one place.

Is Cure Duchenne Legit?

Some Concerns

Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →

IRS 990 Data Cockpit

Where the Money Comes From and Where It Goes

Across stored filings, Cure Duchenne shows contribution history pending. Next enrichment targets: revenue-source fields, IRS BMF classification.

Decision Cockpit

One-Stop Donor, Research, and Peer Context Hub

Donation Decision Flow

From Trust Check to Better Alternatives

Alternative Shopping

Similar Nonprofits Donors Should Compare

Browse the full Category H peer market in California →

Next Best Actions

Keep the Investigation Moving

Cure Duchenne directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.

About Cure Duchenne

Cure Duchenne (EIN: 200299958) is a nonprofit organization based in Mission Viejo, CA, classified under NTEE code H50. The organization reported total revenue of $14.0M and total assets of $30.9M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Cure Duchenne's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.

Organization Overview

Cure Duchenne is a large nonprofit that has been operating for 22 years, with 14 years of IRS 990 filings on record (2010–2023). Revenue has grown at a compound annual rate of 14.2%.

Key Financial Metrics (2023)

From the most recent IRS 990 filing on record:

Financial Health Grade: B

In 2023, Cure Duchenne reported a deficit of $2.9M with expenses exceeding revenue, holds 31.7 months of operating reserves (strong position), has a debt-to-asset ratio of 0.9% (very low leverage).

Financial Trends

Over 14 years of filings (2010–2023), Cure Duchenne's revenue has grown at a compound annual growth rate (CAGR) of 14.2%.

IRS Tax-Exempt Classification

Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.

AI Transparency Report

Mission Effectiveness Score

NonprofitSpending's AI analysis rates Cure Duchenne with a Mission Score of 90 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.

Spending Breakdown

• admin: 10%
• programs: 85%
• fundraising: 5%

According to IRS 990 filings, Cure Duchenne allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.

Key Financial Metrics (2023)

From the most recent IRS 990 filing on record:

• The organization reported a deficit of $2.9M, with expenses exceeding revenue.
• Debt-to-asset ratio: 0.9%.

Executive Compensation Analysis

Cure Duchenne consistently reports 0% officer compensation across all available IRS 990 filings, indicating a strong commitment to directing all funds towards its mission and a high degree of transparency regarding executive pay.

Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.

Red Flags

The following concerns were identified during AI analysis of Cure Duchenne's IRS 990 filings:

• Expenses consistently exceeding revenue in recent years (2021-2023), potentially impacting long-term sustainability if not addressed.

Strengths

The following positive indicators were identified for Cure Duchenne:

• Consistent reporting of 0% officer compensation, indicating high transparency and mission focus.
• Significant growth in assets over the past decade, demonstrating financial stability and capacity.
• Clear alignment between NTEE code (H50) and organizational mission.
• Strong historical revenue generation, including a peak of over $27 million in 2019.

Frequently Asked Questions about Cure Duchenne

Filing History

IRS 990 filing history for Cure Duchenne showing financial trends over 14 years of public records:

Over 14 years of IRS 990 filings (2010–2023), Cure Duchenne's revenue has grown by 463.2%, moving from $1.3M to $7.4M. Total assets increased by 1031.8% over the same period, from $2.4M to $27.1M. Total functional expenses rose by 975.7%, from $953K to $10.2M. In its most recent filing year (2023), Cure Duchenne reported a deficit of $2.9M, with expenses exceeding revenue. The organization holds $256K in liabilities against $27.1M in assets (debt-to-asset ratio: 0.9%), resulting in net assets of $26.8M.

Year-by-Year Financial Summary

• 2023: Revenue of $7.4M, expenses of $10.2M, and assets of $27.1M (revenue +27.9% year-over-year).
• 2022: Revenue of $5.8M, expenses of $9.0M, and assets of $28.4M (revenue +5.7% year-over-year).
• 2021: Revenue of $5.4M, expenses of $7.6M, and assets of $33.2M (revenue +2.1% year-over-year).
• 2020: Revenue of $5.3M, expenses of $6.0M, and assets of $40.9M (revenue -80.6% year-over-year).
• 2019: Revenue of $27.5M, expenses of $5.0M, and assets of $29.8M (revenue +471.8% year-over-year).
• 2018: Revenue of $4.8M, expenses of $4.3M, and assets of $6.8M (revenue +61.3% year-over-year).
• 2017: Revenue of $3.0M, expenses of $2.6M, and assets of $6.2M (revenue +45.6% year-over-year).
• 2016: Revenue of $2.1M, expenses of $3.3M, and assets of $5.9M (revenue +7.8% year-over-year).
• 2015: Revenue of $1.9M, expenses of $2.5M, and assets of $6.4M (revenue -53.1% year-over-year).
• 2014: Revenue of $4.1M, expenses of $1.5M, and assets of $7.1M (revenue +116.1% year-over-year).
• 2013: Revenue of $1.9M, expenses of $2.0M, and assets of $2.8M (revenue +6.0% year-over-year).
• 2012: Revenue of $1.8M, expenses of $2.0M, and assets of $2.1M (revenue +16.1% year-over-year).
• 2011: Revenue of $1.5M, expenses of $1.6M, and assets of $2.4M (revenue +16.7% year-over-year).
• 2010: Revenue of $1.3M, expenses of $953K, and assets of $2.4M.

View Individual Filing Years

Explore detailed financial data from each IRS 990 filing year for Cure Duchenne:

Data Sources and Methodology

This transparency report for Cure Duchenne is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.

IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.

Disclaimer

AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.